In this article, we will discuss Cobimetinib (Dosage Overview). So, let’s get started.
Cobimetinib is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
Limitation of Use: Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with Cobimetinib with vemurafenib.
The recommended dosage regimen of Cobimetinib is 60 mg (three 20 mg tablets) orally taken once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take Cobimetinib with or without food. If a dose of Cobimetinib is missed or if vomiting occurs when the dose is taken, resume dosing with the next scheduled dose.